Straight-ahead summaries built from the official bill text. We keep the source links front and center and leave the decision up to you.
SB3509 • 2026
INS CD-BIOMARKER TESTING
This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.
Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.
INS CD-BIOMARKER TESTING
These notes stay tied to the official amendment files and metadata from the legislature.
Plain English: Illinois General Assembly - Full Text of SB3509 Select Language × The Illinois General Assembly offers the Google Translate™ service for visitor convenience.
Plain English: Illinois General Assembly - Full Text of SB3509 Select Language × The Illinois General Assembly offers the Google Translate™ service for visitor convenience.
Added as Co-Sponsor Sen. Mary Edly-Allen
Sent to the Governor
Third Reading - Short Debate - Passed 109-000-000
Passed Both Houses
Added Alternate Co-Sponsor Rep. Sharon Chung
Added Alternate Co-Sponsor Rep. Yolonda Morris
Added Alternate Co-Sponsor Rep. Margaret A. DeLaRosa
Added Alternate Co-Sponsor Rep. Camille Y. Lilly
Added Alternate Chief Co-Sponsor Rep. Jeff Keicher
Second Reading - Short Debate
Placed on Calendar Order of 3rd Reading - Short Debate
Placed on Calendar 2nd Reading - Short Debate
Do Pass / Short Debate Insurance Committee ; 015-000-000
Assigned to Insurance Committee
Chief House Sponsor Rep. Marcus C. Evans, Jr.
First Reading
Referred to Rules Committee
Recalled to Second Reading
Senate Floor Amendment No. 2 Adopted; Morrison
Placed on Calendar Order of 3rd Reading
Third Reading - Passed; 055-000-000
Arrived in House
Senate Floor Amendment No. 2 Assignments Refers to Insurance
Senate Floor Amendment No. 2 Recommend Do Adopt Insurance ; 011-000-000
Added as Co-Sponsor Sen. Sara Feigenholtz
Added as Co-Sponsor Sen. Adriane Johnson
Added as Co-Sponsor Sen. Graciela Guzmán
Added as Co-Sponsor Sen. Doris Turner
Added as Co-Sponsor Sen. Meg Loughran Cappel
Senate Floor Amendment No. 2 Filed with Secretary by Sen. Julie A. Morrison
Senate Floor Amendment No. 2 Referred to Assignments
Second Reading
Placed on Calendar Order of 3rd Reading March 25, 2026
Added as Co-Sponsor Sen. Mattie Hunter
Added as Co-Sponsor Sen. Christopher Belt
Do Pass as Amended Insurance ; 010-000-000
Placed on Calendar Order of 2nd Reading March 12, 2026
Senate Committee Amendment No. 1 Assignments Refers to Insurance
Senate Committee Amendment No. 1 Adopted
Senate Committee Amendment No. 1 Filed with Secretary by Sen. Julie A. Morrison
Senate Committee Amendment No. 1 Referred to Assignments
Postponed - Insurance
Assigned to Insurance
Filed with Secretary by Sen. Julie A. Morrison
First Reading
Referred to Assignments
INS CD-BIOMARKER TESTING
Illinois General Assembly - Full Text of SB3509 Select Language × The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein. Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet. The English language version is always the official and authoritative version of this website. NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window. Choose Language English Afrikaans Albanian Arabic Armenian Azerbaijani Basque Bengali Bosnian Catalan Croatian Czech Danish Dutch Esperanto Estonian Filipino Finnish French Galician Georgian German Greek Gujarati Haitian Creole Hausa Hawaiian Hebrew Hindi Hungarian Icelandic Indonesian Interlingua Interlingue Inuktitut Irish Italian Japanese Javanese Kannada Khmer Korean Latin Latvian Lithuanian Luxembourgish Macedonian Malagasy Malayalam Maltese Maori Marathi Myanmar Nepali Norwegian Odia Pashto Punjabi Romanian Russian Samoan Sango Sanskrit Sardinian Sindhi Sinhala Slovak Slovenian Somali Southern Sotho Spanish Sundanese Swahili Swedish Tamil Telugu Thai Tigrinya Tonga Turkish Ukrainian Urdu Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Powered by Translate Close Illinois General Assembly Top Navigation Bar Translate Learn Select General Assembly Search the 104th General Assembly Enter search terms for legislation, members, committees, or schedules. ILGA.GOV LEGISLATION & LAWS Bills & Resolutions Public Acts Illinois Compiled Statutes Illinois Constitution Search Legislation Glossary Guide Reports & Inquiry Legislative Reports Special Reports FTP Site Legislator Lookup Capitol Complex Phone Numbers Rules & Regulations Illinois Register Administrative Rules Senate Members Schedules Committees Request for Remote Testimony Journals Transcripts Rules Audio/Video FOIA Information Senate Employment Opportunities Media Guidelines House Members Schedules Committees Submit testimony for House Committees Journals Transcripts Rules Audio/Video FOIA Information House Employment Opportunities Log In Mobile Top Bar Search the 104th General Assembly Enter keywords to search the Illinois General Assembly website. Full Text of SB3509 Home Legislation Full Text SB3509 - 104th General Assembly Bill Status Full Text Votes Witness Slips Select Menu Bill Status Full Text Votes Witness Slips Printer Friendly Version Introduced Engrossed Enrolled Senate Amendment 001 Senate Amendment 002 Printer Friendly Version Introduced Engrossed Enrolled Senate Amendment 001 Senate Amendment 002 Open PDF SB3509 Enrolled LRB104 19966 BAB 33416 b 1 AN ACT concerning regulation. 2 Be it enacted by the People of the State of Illinois, 3 represented in the General Assembly: 4 Section 5. The Illinois Insurance Code is amended by 5 changing Section 356z.46 as follows: 6 (215 ILCS 5/356z.46) 7 Sec. 356z.46. Biomarker testing. 8 (a) As used in this Section: 9 "Biomarker" means a characteristic that is objectively 10 measured and evaluated as an indicator of normal biological 11 processes, pathogenic processes, or pharmacologic responses to 12 a specific therapeutic intervention , including known gene-drug 13 interactions for medications being considered for use or 14 already being used . "Biomarker" includes, but is not limited 15 to, gene mutations , characteristics of genes, or protein 16 expression. 17 "Biomarker testing" means the analysis of a patient's 18 tissue, blood, or other fluid biospecimen for the presence of 19 a biomarker. "Biomarker testing" includes, but is not limited 20 to, single-analyte tests, multi-plex panel tests, protein 21 expression whole exome, and partial or whole genome , and whole 22 transcriptome sequencing and other genomic or molecular 23 sequencing. SB3509 Enrolled - 2 - LRB104 19966 BAB 33416 b 1 "Consensus statement" means a statement developed by an 2 independent, multidisciplinary panel of experts using a 3 transparent methodology and reporting structure, with a 4 conflict of interest policy, that is aimed at specific 5 clinical circumstances, and the statement is based on the best 6 available evidence for the purpose of optimizing the outcomes 7 of clinical care. 8 "Nationally recognized clinical practice guidelines" means 9 evidence-based clinical practice guidelines developed by 10 independent organizations or medical professional societies 11 using a transparent methodology and reporting structure, with 12 a conflict of interest policy, that establish standards of 13 care informed by a systematic review of evidence and an 14 assessment of the benefits and risks of alternative care 15 options and that include recommendations intended to optimize 16 patient care. 17 (b) A group or individual policy of accident and health 18 insurance or managed care plan amended, delivered, issued, or 19 renewed on or after January 1, 2022 shall include coverage for 20 biomarker testing as defined in this Section pursuant to 21 criteria established under subsection (d). 22 (c) Biomarker testing shall be covered and conducted in an 23 efficient manner to provide the most complete range of results 24 to the patient's health care provider without requiring 25 multiple biopsies, biospecimen samples, or other delays or 26 disruptions in patient care. SB3509 Enrolled - 3 - LRB104 19966 BAB 33416 b 1 (d) Biomarker testing must be covered for the purposes of 2 diagnosis, treatment, appropriate management, or ongoing 3 monitoring of an enrollee's disease or condition when the test 4 is supported by medical and scientific evidence, including, 5 but not limited to , any one of the following : 6 (1) labeled indications for an FDA-approved or 7 FDA-cleared test ; or 8 (2) indicated tests for an FDA-approved drug; 9 (3) warnings and precautions on FDA-approved drug 10 labels; 11 (4) (2) federal Centers for Medicare and Medicaid 12 Services National Coverage Determinations or any Medicare 13 Administrative Contractor (MAC) Local Coverage 14 Determinations and associated Local Coverage Articles ; or 15 (5) testing recommendations or considerations from: 16 (A) (3) nationally recognized clinical practice 17 guidelines; or 18 (B) a consensus statement. 19 (4) consensus statements; 20 (5) professional society recommendations; 21 (6) peer-reviewed literature, biomedical compendia, 22 and other medical literature that meet the criteria of the 23 National Institutes of Health's National Library of 24 Medicine for indexing in Index Medicus, Excerpta Medicus, 25 Medline, and MEDLARS database of Health Services 26 Technology Assessment Research; and SB3509 Enrolled - 4 - LRB104 19966 BAB 33416 b 1 (7) peer-reviewed scientific studies published in or 2 accepted for publication by medical journals that meet 3 nationally recognized requirements for scientific 4 manuscripts and that submit most of their published 5 articles for review by experts who are not part of the 6 editorial staff. 7 (e) The requirements set forth in this Section are subject 8 to and shall operate in accordance with subsection (b) of 9 Section 20 of the Prior Authorization Reform Act and Section 10 45 of the Managed Care Reform and Patient Rights Act. When 11 coverage of biomarker testing for the purpose of diagnosis, 12 treatment, or ongoing monitoring of any medical condition is 13 restricted for use by a group or individual policy of accident 14 and health insurance or managed care plan, the patient and 15 prescribing practitioner shall have access to a clear, readily 16 accessible, and convenient processes to request an exception. 17 The process shall be made readily accessible on the insurer's 18 website. 19 (f) The changes made to this Section by this amendatory 20 Act of the 104th General Assembly apply to policies, 21 contracts, and certificates of insurance amended, delivered, 22 issued, or renewed on or after January 1, 2028. 23 (Source: P.A. 102-203, eff. 1-1-22; 102-813, eff. 5-13-22.) 24 Section 99. Effective date. This Act takes effect January 25 1, 2028. Footer Disclaimer This site is maintained for the Illinois General Assembly by the Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706. Contact ILGA Webmaster ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies. Read About Cookies ILGA.GOV 2026 ILGA.gov | All Rights Reserved | ADA | Disclaimers | Learn This site is maintained for the Illinois General Assembly by the Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706. Contact ILGA Webmaster ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies. Read About Cookies ILGA.GOV 2026 ILGA.gov | All Rights Reserved | ADA | Disclaimers | Learn